Makes specialty chemicals across four segments, with pharmaceutical intermediates the dominant business. Pharma intermediates contributed 87.7% of FY26 revenue (₹11,741 Mn), supplying advanced intermediates and CDMO products to global pharmaceutical customers; the segment grew 76.5% YoY in Q1 FY27 to ₹292.7 cr. Commodity chemicals accounted for 11.2% of FY26 revenue and are being deliberately phased out as lower-margin products are replaced by higher-margin specialty offerings. Semiconductor chemicals — where the company is India's only photoresist manufacturer — made up 1.2% of FY26 revenue, with a new IndiChem plant in Korea due to start commercial revenue from FY28. Battery chemicals commercial supply commenced in Q1 FY27 after trial runs, targeting full 4,000 MT capacity (2,000 MT VC + 2,000 MT FEC) within three years. The cost base is dominated by raw materials at 44.4% of FY26 revenue, with capex at 24.5% reflecting heavy capacity expansion across plants. Management has guided to 25% revenue growth for FY27 with stable margins. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. Pharmaceutical Intermediates (88%), Commodity Chemicals (11%), Semiconductor Chemicals (1%), Battery Chemicals. Specialty chemicals manufacturer anchored by pharma intermediates, diversifying into battery and semiconductor chemicals
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 520 | 617 | 717 | 1,007 | 1,339 |
| EBITDA (ex other income) | 105 | 123 | 96 | 232 | 480 |
| margin % | 20.2 | 19.9 | 13.4 | 23.0 | 35.9 |
| Owners' profit | 72 | 0 | 43 | 159 | 356 |
| EPS, as reported (₹) | 21.03 | 22.86 | 11.67 | 19.81 | 43.51 |
| ROE % · ROCE % | 13.8 · 18.5 | 14.0 · 19.0 | 7.1 · 10.8 | 12.2 · 16.5 | 20.8 · 27.7 |
| Debt / equity (x) | 0.00 | 0.01 | 0.32 | 0.01 | 0.02 |
| Cash from operations | (9) | 66 | 125 | 118 | 292 |
| Capex | 0 | (96) | (280) | (195) | (328) |
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 247 | 275 | 308 | 207 | 306 | 393 | 433 | 330 |
| Profit before tax | 50 | 63 | 83 | 58 | 96 | 145 | 184 | 104 |
| Net profit | 38 | 45 | 63 | 44 | 72 | 106 | 134 | 75 |
| EPS (₹) | 9.38 | 11.35 | 7.80 | 5.41 | 8.82 | 13.19 | 16.09 | 9.07 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,41,471 | 36.5 | 5.26 | 23.7 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,47,033 | 84.6 | 14.74 | 63.7 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,68,062 | 79.3 | 9.56 | 41.5 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,11,686 | 24.9 | 3.78 | 14.5 | 17.3 | 18.0 | 12.4 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 10 Sept 2026 · Acutaas Chemicals gets patent for 2,4-Dimethylthiophenol process, total patents now 11 | business updates | medium | — | — |
| 4 Sept 2026 · Acutaas Chemicals inaugurates new pilot plant at Sachin Unit 1 | capex operations | medium | — | — |
| 31 Aug 2026 · Newspaper ad on 19th AGM notice and Annual Report dispatch for FY 2025-26 | compliance | minimal | — | — |
| 29 Aug 2026 · Acutaas Chemicals informs shareholders about TDS rules on final dividend | compliance | low | — | — |
| 29 Aug 2026 · Record date fixed for Final Dividend FY 2025-26 at Rs 2.50 per share | corporate actions | high | — | — |
| 29 Aug 2026 · Acutaas Chemicals submits BRSR for FY 2025-26 | compliance | low | — | — |
| 29 Aug 2026 · Acutaas FY26 Annual Report: Revenue up 33%, PAT up 122% | results | high | — | — |
| 29 Aug 2026 · Acutaas Chemicals 19th AGM notice on September 24, 2026 | board shareholder meetings | low | — | — |
| 28 Aug 2026 · Acutaas unit Indichem opens semiconductor plant in South Korea | capex operations | high | — | — |
| 24 Aug 2026 · Newspaper publication for 19th AGM on September 24, 2026 | compliance | minimal | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions |
| 25.2 |
| CIPLA LTD | 1,10,352 | 32.7 | 3.20 | 16.9 | 11.2 | 14.7 | 8.0 | 19.7 |
| LAURUS LABS LIMITED | 1,06,375 | 97.2 | 19.59 | 59.3 | 16.4 | 17.2 | 7.2 | 32.0 |
| DR. REDDY S LABORATORIES | 97,319 | 30.1 | 2.55 | 13.1 | 10.9 | 13.0 | 12.1 | 15.0 |
| AUROBINDO PHARMA LTD | 96,656 | 26.3 | 2.55 | 13.4 | 9.2 | 12.6 | 6.3 | 23.0 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 71.7 | 28.9 | 145 of 169 | 14% |
| P/B | 16.2 | 3.3 | 155 of 163 | 5% |
| ROCE | 27.5 | 10.8 | 12 of 183 | 94% |
| ROE | 20.8 | 10.4 | 19 of 171 | 89% |
| Debt / Equity | 0.0 | 0.1 | 55 of 171 | 68% |
| EBITDA margin | 34.8 | 17.5 | 19 of 165 | 89% |
| Revenue growth | 59.1 | 16.3 | 17 of 161 | 90% |
| Profit growth | 70.4 | 30.9 | 49 of 158 | 69% |
| Market cap | 27697 | 839 | 25 of 182 | 87% |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
